Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.48 |
| ▸ | GPR34 | Q9UPC5 | 3/20 | 0.46 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.45 |
| ▸ | TNF | P01375 | 1/20 | 0.45 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.44 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.44 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.43 |
| ▸ | CDC25B | P30305 | 1/20 | 0.43 |
| ▸ | CTSC | P53634 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16822567 | 1.00 | MDM4 (0.48) | MDM4TP53MDM2GPR34SLC17A5 | |
| SCHEMBL16822472 | 0.93 | PTPN1 (0.44) | MDM4TP53MDM2TNFPTPN1 | |
| SCHEMBL20112939 | 0.93 | PTPN1 (0.44) | MDM4TP53MDM2TNFPTPN1 | |
| SCHEMBL16822595 | 0.89 | MDM4 (0.49) | MDM4TP53MDM2GPR34SLC17A5 | |
| SCHEMBL28078868 | 0.89 | MDM4 (0.49) | MDM4TP53MDM2GPR34SLC17A5 | |
| SCHEMBL22444667 | 0.88 | MDM2 (0.53) | MDM4TP53MDM2SLC17A5TNF | |
| SCHEMBL20112950 | 0.87 | MDM4 (0.40) | MDM4TP53MDM2GPR34ITGB3 | |
| SCHEMBL2305316 | 0.86 | ITGB3 (0.57) | GPR34ITGB3ITGA2BPTPN1 | |
| SCHEMBL29401248 | 0.86 | ITGB3 (0.57) | GPR34ITGB3ITGA2BPTPN1 | |
| SCHEMBL2305323 | 0.86 | ITGB3 (0.57) | GPR34ITGB3ITGA2BPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107614504-B | Crystals of carboxamide compound | 卫材R&D管理有限公司 | 2019-12-24 | — | — | CN | disclosed |
| US-10259817-B2 | Crystal (6S,9aS)-N-benzyl-8-({6-[3-(4-ethylpiperazin-1-yl)azetidin-1-yl]pyridin-2-yl}methyl)-6-(2-fluoro-4-hydroxybenzyl)-4,7-dioxo-2-(prop-2-en-1-yl)hexahydro-2H-pyrazino[2,1-c][1,2,4]triazine-1(6H)-carboxamide | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2019-04-16 | — | — | US | disclosed |
| US-10221183-B2 | — | — | 2019-03-05 | — | — | US | disclosed |
| CN-105873932-A | (6S,9aS) -N-benzyl-6- [ (4-hydroxyphenyl) methyl ] -4, 7-dioxo-8- ({6- [3- (piperazin-1-yl) azetidin-1-yl ] pyridin-2-yl } methyl) -2- (prop-2-en-1-yl) -octahydro-1H-pyrazino [2,1-c ] [1,2,4] triazine-1-carboxamide compound | 卫材R&D管理有限公司 | 2016-08-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10221183-B2 | — | NT5C, HTR2C, HTR3C | MDM4 936/4885TP53 3998/4885MDM2 1884/4885 |
| US-10259817-B2 | Crystal (6S,9aS)-N-benzyl-8-({6-[3-(4-ethylpiperazin-1-yl)azetidin-1-yl]pyridin-2-yl}methyl)-6-(2-fluoro-4-hydroxybenzyl)-4,7-dioxo-2-(prop-2-en-1-yl)hexahydro-2H-pyrazino[2,1-c][1,2,4]triazine-1(6H)-carboxamide | NT5C, HTR2C, HTR1D | MDM4 3121/4885TP53 4533/4885MDM2 2184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.